Mahboobeh Mahdavinia
Allergy & Immunology · Houston, TXNPI 1659514131
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,660 of the $19,733 with a category attached, or 64.2%. 17 manufacturers reported payments, led by Eli Lilly at 52.5% of the total. 2025 is the largest year on record at $14,012, more than ten times the $135 reported in 2019.
Across 81 payments — averaging $243.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$10K
- Sanofi$5K
- Optinose US, Inc.$2K
- Blueprint Medicines Corporation$518
- AstraZeneca$328
- Regeneron Healthcare Solutions, Inc.$323
- plus $684 from 11 others
Across 4 payments — averaging $14,635 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Optinose US, Inc.$59K
What the payments were for
- Consulting fees$12,66064%
- Grants$3,00015%
- Travel & lodging$1,2366%
- Food & beverage$2,66213%
- Education$1751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 16 | $10,356 |
| Sanofi | 9 | $5,429 |
| Optinose US, Inc. | 5 | $2,095 |
| Blueprint Medicines Corporation | 4 | $518 |
| AstraZeneca | 10 | $328 |
| Regeneron Healthcare Solutions, Inc. | 10 | $323 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $135 |
| CSL Behring | 4 | $96 |
| Novartis | 5 | $96 |
| Grifols USA, LLC | 4 | $81 |
| Pharming Healthcare, Inc. | 3 | $80 |
| Alk-abello, Inc | 1 | $70 |
| Lilly USA, LLC | 2 | $61 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $15 |
| GC Biopharma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,733 in reported general payments places this provider in the 80th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 52 | $189,454 |
| XolairOmalizumab | 17 | $63,853 |
| Ipratropium Bromide | 12 | $357 |
| Fluticasone Propionate | 16 | $163 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Houston
- Juan ZambranoHouston$146K
- Ekta PereraHouston$75K
- Joud HajjarHouston$52K
- Sara AnvariHouston$35K
- Sarah NicholasHouston$32K
- Julie PatelHouston$24K
- Rama YerramsettiHouston$24K
- Christopher CollacoHouston$21K
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.